Sphera Funds Management’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
Other funds holding MLYS
Sphera Funds Management's MLYS Position: Q3 2026 in Review
Sphera Funds Management reduced its Mineralys Therapeutics (MLYS) stake by 10% in Q3 2026, selling an estimated $4.03M and leaving 1,321,861 shares worth $33.2M. The position accounts for 4.7% of the portfolio, ranked #1.
Sphera Funds Management first reported a position in MLYS in Q1 2023 and has held it in 15 quarters since. The position peaked at $39.7M in Q2 2026. 216 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.
- Sphera Funds Management held 1,321,861 shares of Mineralys Therapeutics worth $33.2M as of Q3 2026.
- Sphera Funds Management sold 148,110 Mineralys Therapeutics shares in Q3 2026, an estimated $4.03M.
- Mineralys Therapeutics made up 4.7% of Sphera Funds Management's portfolio in Q3 2026, its #1 holding.
- Sphera Funds Management first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 15 quarters since.
- Sphera Funds Management's Mineralys Therapeutics position peaked at $39.7M in Q2 2026.
- 216 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.
Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.